Cimzia(R) Study Shows Rapid Reduction Of Symptoms And Inhibition Of Joint Damage Progression In RA

UCB announced today the online publication of pivotal study results showing CIMZIA^ (certolizumab pegol), the only PEGylated anti-TNF (Tumor Necrosis Factor) together with methotrexate (MTX) rapidly reduced symptoms of disease and inhibited progression of joint damage in adult patients with active rheumatoid arthritis (RA), with sustained results for up to one year.